BEYONDSPRING INC

BEYONDSPRING INC

Share · KYG108301006 · BYSI (XNAS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BEYONDSPRING INC
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
6
2
1
0
No Price
29.04.2026 15:49
Current Prices from BEYONDSPRING INC
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
BYSI
USD
29.04.2026 15:49
1,52 USD
0,01 USD
+0,66 %
IEXG: IEX
IEX
BYSI
USD
29.04.2026 15:30
1,49 USD
-0,02 USD
-1,32 %
Share Float & Liquidity
Free Float 75,86 %
Shares Float 31,2 M
Shares Outstanding 41,12 M
Invested Funds

The following funds have invested in BEYONDSPRING INC:

Fund
iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF USD (Dist)
Vol. in million
78,52
Percentage (%)
0,08 %
Company Profile for BEYONDSPRING INC Share
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Company Data

Name BEYONDSPRING INC
Company BeyondSpring Inc.
Symbol BYSI
Website https://www.beyondspringpharma.com
Primary Exchange XNAS NASDAQ
ISIN KYG108301006
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Lan Huang
Market Capitalization 62 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 28 Liberty Street, 10005 Florham Park
IPO Date 2017-03-09

Ticker Symbols

Name Symbol
NASDAQ BYSI
More Shares
Investors who hold BEYONDSPRING INC also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COMCAST CORP - CLASS A
COMCAST CORP - CLASS A Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
ELIOTT CAP. 19/22 ZO CV
ELIOTT CAP. 19/22 ZO CV Bond
GRIECHENLAND 12-27 5
GRIECHENLAND 12-27 5 Bond
HNT
HNT Crypto
IDEXX LABORATORIES INC
IDEXX LABORATORIES INC Share
INTEL CORP
INTEL CORP Share
MICROSOFT CORP
MICROSOFT CORP Share
PROS S INC
PROS S INC Share
QIAGEN NV (alt)
QIAGEN NV (alt) Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share